Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionMissed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases
Parchinski K, Neirinckx V, Frank C, Di Paola A, Tarfa A, Shenoi S, Vander WyK B, Roth P, Ghantous T, Wegman M, Strong M, Levin F, Brady K, Nunes E, Litwin A, Springer S. Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases 2024, 11: ofae366. PMID: 39022389, PMCID: PMC11252843, DOI: 10.1093/ofid/ofae366.Peer-Reviewed Original Research